The company behind AOD-9604 knew back in 2007, after six clinical trials of 925 patients, that the drug had completely failed to treat obesity
Two clinically studied peptides
AOD-9604 Side Effects and Complications Currently, only two studies (METAOD005 and METAOD006) have investigated the long-term safety of AOD-9604
Deficiency can lead to irreversible neurological damage, including peripheral neuropathy (numbness and tingling in hands and feet), difficulty walking, memory problems, and in severe cases, dementia-like symptoms
The same compound that repairs a torn Achilles tendon in a rat also appears to attenuate the neurological consequences of dopamine depletion, pointing to a shared upstream mechanism that remains an active area of investigation
Some peptides reconstitute better in saline than plain water